Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study.

Pappo, Alberto S.; Patel, Shreenal; Crowley, J.; Reinke, Denise K.; Staddon, Arthur P.; Kuenkele, Klaus Peter; Chawla, S. P.; Benjamin, Robert S.; Helman, L. J.; Baker, Laurence H.

doi:10.1200/jco.2010.28.15_suppl.10000

Cited by 37 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite widespread enthusiasm about IGF-1R blockade for cancer therapy and a clear benefit observed in a small subset of patients treated with single-agent IGF-1R antagonists (8,9), the anticancer effects in advanced clinical trials have been ordinary and unsustained (10)(11)(12)30) through yet to be identified mechanisms of resistance. We also observed that a large number of human HNSCC and NSCLC cell lines were resistant to the IGF-1R-blocking mAb cixutumumab.…”

Section: Discussionmentioning

confidence: 99%

Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β 3-Src Pathway

Shin

Min

et al. 2013

JNCI: Journal of the National Cancer Institute

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β 3-Src Pathway

Shin

Min

et al. 2013

JNCI: Journal of the National Cancer Institute

View full text Add to dashboard Cite

“…The most attractive candidate agents are the IGF-1R inhibitors, which have produced responses as single agents in about 10% of patients with relapsed disease. 85 Other potential agents include inhibitors of PDGFR, mTOR (in combination with IGF-1R inhibitors), SRC, VEGF, and CD99, as well as the Seneca Valley virus and the kinesin spindle protein inhibitor ispinesib. 69,86 …”

Section: Central Nervous System Tumorsmentioning

confidence: 99%

Challenging issues in pediatric oncology

et al. 2011

View full text Add to dashboard Cite

Improvements in protocol-driven clinical trials and supportive care for children and adolescents with cancer have reduced mortality rates by more than 50% over the past three decades. Overall, the 5-year survival rate for pediatric cancer patients has increased to approximately 80%. Recognition of the biological heterogeneity within specific subtypes of cancer, the discovery of genetic lesions that drive malignant transformation and cancer progression, and improved understanding of the basis of drug resistance will undoubtedly catalyze further advances in risk-directed treatments and the development of targeted therapies, boosting the cure rates further. Emerging new treatments include novel formulations of existing chemotherapeutic agents, monoclonal antibodies against cancer-associated antigens, and molecular therapies that target genetic lesions and their associated signaling pathways. Recent findings that link pharmacogenomic variations with drug exposure, adverse effects, and efficacy should accelerate efforts to develop personalized therapy for individual patients. Finally, palliative care should be included as an essential part of cancer management to prevent and relieve the suffering and to improve the quality of life of patients and their families.

show abstract

“…A large phase 2 trial in patients with recurrent or refractory sarcomas of R1507, a recombinant human monoclonal antibody to IGF-1R, demonstrated modest activity in rhabdomyosarcoma (13% ORR or 5/38 patients). Minimal activity (2.4% ORR and 26% SD in 167 patients) was seen in other STS subtypes [111,112]. Several other IGF-1R monoclonal antibodies are currently being tested in sarcoma patients; these efforts were recently reviewed [113].…”

Section: Insulin-like Growth Factor-1 Receptor (Igf-1r) Inhibitorsmentioning

confidence: 99%

Systematic Therapy for Unresectable or Metastatic Soft-Tissue Sarcomas: Past, Present, and Future

Morgan

Cranmer

2011

Curr Oncol Rep

View full text Add to dashboard Cite

Unresectable or metastatic disease occurs in 40% to 60% of soft-tissue sarcoma (STS) patients and portends a poor prognosis. For decades, doxorubicin has formed the backbone of systemic treatment, with response rates of approximately 26%. Patients progressing following first-line therapy were left with few proven options. No other cytotoxic chemotherapy agent or combination has demonstrated superiority to doxorubicin. Advances in targeted therapy of STS have been hindered by STS heterogeneity and poorly understood disease biology. Despite challenges, progress has been made in specific STS subtypes. Here, we highlight the challenges, progress, and lessons learned from STS trials published in the last 20 to 25 years.

show abstract

Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study.

Cited by 37 publications

References 0 publications

Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β 3-Src Pathway

Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β 3-Src Pathway

Challenging issues in pediatric oncology

Systematic Therapy for Unresectable or Metastatic Soft-Tissue Sarcomas: Past, Present, and Future

Contact Info

Product

Resources

About